Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorThe Cleveland Clinic
About this trial
This is a cross-sectional study in patients with Type 1 diabetes (TID) and chronic kidney disease (CKD) to test if time in range (TIR) affects the degree of hyperglycemia required for monocyte activation, podocyte injury, and assess if monocyte activation is attenuated by glucagon-like peptide (GLP-1) agonist treatment ex vivo.
Eligibility criteria
Qualifiers
Adults, males or females diagnosed with T1D
Age 18-65 years
Diagnosed with CKD (eGFR 60-90 ml/min/1.73 m2)
Diagnosed with albuminuria (UACR 30-500 mg/g)
Disqualifiers
Hemoglobin <9
On GLP-1 agonist or DPP4 inhibitor or sodium-glucose co-transporter-2 inhibitors use within 30 days
pregnancy or plans to become pregnant
On steroids
Trial design
Treatments tested in this trial
- Not listed
Trial groups
60 Participants
are grouped into 1 trial groupSponsors and collaborators
The Cleveland Clinic
Lead sponsor
Stanford University
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Source ClinicalTrials.gov